Corcept Therapeutics (CORT) Competitors $58.32 -1.15 (-1.93%) Closing price 04:00 PM EasternExtended Trading$59.46 +1.15 (+1.96%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock CORT vs. RPRX, JAZZ, PRGO, SUPN, PCRX, OMER, NKTR, CPIX, ASMB, and LLYShould you be buying Corcept Therapeutics stock or one of its competitors? The main competitors of Corcept Therapeutics include Royalty Pharma (RPRX), Jazz Pharmaceuticals (JAZZ), Perrigo (PRGO), Supernus Pharmaceuticals (SUPN), Pacira BioSciences (PCRX), Omeros (OMER), Nektar Therapeutics (NKTR), Cumberland Pharmaceuticals (CPIX), Assembly Biosciences (ASMB), and Eli Lilly and Company (LLY). These companies are all part of the "pharmaceuticals" industry. Corcept Therapeutics vs. Royalty Pharma Jazz Pharmaceuticals Perrigo Supernus Pharmaceuticals Pacira BioSciences Omeros Nektar Therapeutics Cumberland Pharmaceuticals Assembly Biosciences Eli Lilly and Company Royalty Pharma (NASDAQ:RPRX) and Corcept Therapeutics (NASDAQ:CORT) are both finance companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, valuation, profitability, analyst recommendations, media sentiment and community ranking. Does the media favor RPRX or CORT? In the previous week, Corcept Therapeutics had 9 more articles in the media than Royalty Pharma. MarketBeat recorded 18 mentions for Corcept Therapeutics and 9 mentions for Royalty Pharma. Royalty Pharma's average media sentiment score of 1.68 beat Corcept Therapeutics' score of 0.83 indicating that Royalty Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Royalty Pharma 8 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Corcept Therapeutics 7 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community favor RPRX or CORT? Corcept Therapeutics received 218 more outperform votes than Royalty Pharma when rated by MarketBeat users. Likewise, 71.22% of users gave Corcept Therapeutics an outperform vote while only 67.92% of users gave Royalty Pharma an outperform vote. CompanyUnderperformOutperformRoyalty PharmaOutperform Votes32467.92% Underperform Votes15332.08% Corcept TherapeuticsOutperform Votes54271.22% Underperform Votes21928.78% Do analysts rate RPRX or CORT? Royalty Pharma presently has a consensus price target of $41.60, indicating a potential upside of 23.22%. Corcept Therapeutics has a consensus price target of $99.75, indicating a potential upside of 71.04%. Given Corcept Therapeutics' higher possible upside, analysts plainly believe Corcept Therapeutics is more favorable than Royalty Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Royalty Pharma 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.00Corcept Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is RPRX or CORT more profitable? Royalty Pharma has a net margin of 37.94% compared to Corcept Therapeutics' net margin of 22.35%. Corcept Therapeutics' return on equity of 24.54% beat Royalty Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Royalty Pharma37.94% 24.40% 14.01% Corcept Therapeutics 22.35%24.54%20.24% Which has more volatility and risk, RPRX or CORT? Royalty Pharma has a beta of 0.47, suggesting that its share price is 53% less volatile than the S&P 500. Comparatively, Corcept Therapeutics has a beta of 0.61, suggesting that its share price is 39% less volatile than the S&P 500. Which has better valuation and earnings, RPRX or CORT? Royalty Pharma has higher revenue and earnings than Corcept Therapeutics. Royalty Pharma is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRoyalty Pharma$2.26B8.60$858.98M$1.4523.28Corcept Therapeutics$675.04M9.11$106.14M$1.2447.03 Do institutionals & insiders hold more shares of RPRX or CORT? 54.3% of Royalty Pharma shares are held by institutional investors. Comparatively, 93.6% of Corcept Therapeutics shares are held by institutional investors. 18.9% of Royalty Pharma shares are held by company insiders. Comparatively, 20.5% of Corcept Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. SummaryCorcept Therapeutics beats Royalty Pharma on 12 of the 18 factors compared between the two stocks. Remove Ads Get Corcept Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CORT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CORT vs. The Competition Export to ExcelMetricCorcept TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.15B$6.99B$5.68B$8.32BDividend YieldN/A2.72%4.55%4.02%P/E Ratio46.297.2324.5519.25Price / Sales9.11230.77395.7294.09Price / Cash67.9665.6738.1634.64Price / Book11.856.617.064.46Net Income$106.14M$142.13M$3.19B$247.07M7 Day Performance3.22%2.79%1.49%3.05%1 Month Performance-4.75%2.70%5.87%-2.85%1 Year Performance136.50%-4.42%14.94%4.63% Corcept Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CORTCorcept Therapeutics4.4691 of 5 stars$58.32-1.9%$99.75+71.0%+142.7%$6.15B$675.04M46.29300Analyst RevisionRPRXRoyalty Pharma4.7745 of 5 stars$33.02+0.8%$41.60+26.0%+11.5%$19.03B$2.26B22.7780Positive NewsJAZZJazz Pharmaceuticals4.9487 of 5 stars$140.22+1.6%$187.71+33.9%+16.6%$8.52B$4.07B19.753,200Positive NewsPRGOPerrigo4.8743 of 5 stars$28.27+3.7%$33.00+16.7%-11.4%$3.86B$4.37B-24.169,140Analyst RevisionPositive NewsSUPNSupernus Pharmaceuticals1.2161 of 5 stars$32.16+2.9%$36.00+11.9%-5.3%$1.79B$661.82M30.06580Analyst DowngradePCRXPacira BioSciences3.922 of 5 stars$23.31+1.9%$27.22+16.8%-13.4%$1.08B$700.97M-11.48720Analyst RevisionPositive NewsOMEROmeros3.6717 of 5 stars$8.52+1.2%$22.50+164.1%+165.3%$493.73MN/A-3.69210NKTRNektar Therapeutics4.4668 of 5 stars$0.91+1.4%$4.92+440.7%-5.8%$167.73M$93.14M-1.08220CPIXCumberland Pharmaceuticals0.5379 of 5 stars$5.17-5.3%N/A+143.1%$72.22M$37.87M-6.7180ASMBAssembly Biosciences3.9604 of 5 stars$10.59-2.5%$35.00+230.5%-14.3%$67.31M$28.33M0.00100Earnings ReportUpcoming EarningsAnalyst DowngradeAnalyst RevisionNews CoverageLLYEli Lilly and Company4.6172 of 5 stars$825.48+1.5%$1,009.72+22.3%+12.4%$782.70B$45.04B70.4939,000Analyst RevisionPositive News Remove Ads Related Companies and Tools Related Companies Royalty Pharma Competitors Jazz Pharmaceuticals Competitors Perrigo Competitors Supernus Pharmaceuticals Competitors Pacira BioSciences Competitors Omeros Competitors Nektar Therapeutics Competitors Cumberland Pharmaceuticals Competitors Assembly Biosciences Competitors Eli Lilly and Company Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CORT) was last updated on 3/25/2025 by MarketBeat.com Staff From Our PartnersYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | Sponsored“Amazon Coin” set to outperform BitcoinChris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Corcept Therapeutics Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Corcept Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CORT Stock Free CORT Stock Alerts